Can I Take Omega-3 (EPA/DHA) with Repatha (Evolocumab)?

How Evolocumab and Omega-3 Work in the Body

Evolocumab and omega-3 fatty acids target different parts of lipid metabolism with zero overlap in their metabolic pathways. Understanding why they do not interfere with each other starts with how each agent is processed.

Evolocumab: A Monoclonal Antibody, Not a Small Molecule

Evolocumab (Repatha) is a fully human monoclonal antibody that binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) in the bloodstream [1]. By blocking PCSK9, it prevents the degradation of LDL receptors on hepatocyte surfaces. More LDL receptors survive, more circulating LDL particles get cleared. The drug is administered by subcutaneous injection every 2 or 4 weeks and is broken down by proteolysis (the same way the body breaks down any protein), not by cytochrome P450 enzymes in the liver [2].

This distinction matters. Because evolocumab bypasses CYP-mediated metabolism entirely, the standard drug-supplement interactions that affect statins, fibrates, or oral anticoagulants simply do not apply here.

Omega-3 Fatty Acids: Triglyceride Reduction Through VLDL Suppression

EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) lower triglycerides by reducing hepatic very-low-density lipoprotein (VLDL) production and accelerating triglyceride clearance from plasma [3]. At prescription doses (2-4 g/day of EPA+DHA), triglyceride reductions of 20-45% are typical. Omega-3 fatty acids are incorporated into cell membranes and undergo beta-oxidation. They do not compete for CYP enzymes at clinically relevant doses [4].

Why These Two Agents Do Not Clash

Evolocumab works in the bloodstream as a protein. Omega-3 fatty acids work inside hepatocytes and cell membranes as lipid substrates. Their distribution, metabolism, and elimination pathways do not intersect. No pharmacokinetic interaction has been reported in post-marketing surveillance, clinical trials, or the Natural Medicines Comprehensive Database [5].

Is There a Pharmacodynamic Interaction?

The interaction between evolocumab and omega-3 is pharmacodynamic, not pharmacokinetic, and it is additive rather than antagonistic. Both agents improve cardiovascular lipid profiles, but they act on different lipid fractions.

Complementary Lipid Effects

Evolocumab targets LDL-C. In the FOURIER trial (N=27,564), evolocumab 140 mg every 2 weeks reduced LDL cholesterol by 59% compared to placebo (from a median of 92 mg/dL to 30 mg/dL) and cut the composite of cardiovascular death, myocardial infarction, or stroke by 15% over 2.2 years of median follow-up [6]. Omega-3 targets triglycerides. In REDUCE-IT (N=8,179), icosapent ethyl 4 g/day reduced the primary composite endpoint of cardiovascular death, nonfatal MI, nonfatal stroke, coronary revascularization, or unstable angina by 25% (HR 0.75, 95% CI 0.68-0.83, P<0.001) [7].

Patients with elevated LDL and elevated triglycerides (a common pattern in mixed dyslipidemia and metabolic syndrome) may benefit from both pathways simultaneously. The 2018 AHA/ACC cholesterol guideline acknowledges that residual cardiovascular risk persists even after LDL lowering, and triglyceride-rich lipoproteins contribute to that residual risk [8].

The Antiplatelet Question

High-dose omega-3 fatty acids have a mild antiplatelet effect. EPA competes with arachidonic acid for cyclooxygenase, shifting the balance from thromboxane A2 (prothrombotic) toward thromboxane A3 (weakly prothrombotic) [9]. In practice, this effect is modest. A 2018 Cochrane review of 79 trials (N=112,059) found no significant increase in major bleeding events with omega-3 supplementation [10].

For patients taking evolocumab alone, this is a non-issue. Evolocumab has no antiplatelet or anticoagulant properties. The concern arises only when a third agent is present: aspirin, clopidogrel, warfarin, or a direct oral anticoagulant. If you take Repatha plus a blood thinner plus high-dose omega-3, mention all three to your cardiologist so bleeding risk can be monitored.

What the Clinical Evidence Shows

No dedicated randomized trial has studied evolocumab plus omega-3 as a specific combination. The evidence supporting co-administration comes from three lines of data.

Line 1: Trial Populations That Used Both

In FOURIER, statin background therapy was required, and concomitant medications were permitted at investigator discretion. The trial did not exclude omega-3 supplement users, and no safety signal emerged related to fish oil co-administration [6]. The Repatha prescribing information does not list omega-3 fatty acids as a contraindication or precaution [2].

Line 2: Shared Patient Populations

The American Heart Association recommends prescription omega-3 (specifically icosapent ethyl) as an add-on to statin therapy for patients with triglycerides between 135 and 499 mg/dL and established ASCVD or diabetes with additional risk factors [11]. Many of these same patients qualify for PCSK9 inhibitor therapy if LDL remains above 70 mg/dL despite maximally tolerated statin doses. The overlap is large and growing as guidelines expand indications for both drug classes.

Dr. Deepak Bhatt, lead investigator of the REDUCE-IT trial, stated: "EPA reduced cardiovascular events on top of statin therapy. The mechanism appears to go beyond triglyceride lowering alone, involving anti-inflammatory and membrane-stabilizing effects" [7]. This multi-mechanistic benefit supports the rationale for layering EPA on top of other lipid-lowering therapies, including PCSK9 inhibitors.

Line 3: Mechanistic Independence

A 2020 review in the Journal of the American College of Cardiology summarized the independent pathways of PCSK9 inhibition, statin therapy, and omega-3 fatty acids, concluding that "combination approaches targeting LDL-C, triglycerides, and inflammation represent a rational strategy for residual risk reduction" [12]. The 2019 ESC/EAS dyslipidemia guidelines similarly endorse multi-target lipid management when monotherapy fails to achieve risk-appropriate goals [13].

Dosing and Timing Considerations

Because there is no interaction requiring separation, you do not need to time your omega-3 dose around your Repatha injection. Take each on whatever schedule works best for adherence.

Evolocumab Dosing

Repatha is given as 140 mg subcutaneously every 2 weeks or 420 mg every month. Both regimens produce equivalent LDL reductions over time [2]. The injection can be administered at any time of day, with or without food.

Omega-3 Dosing: OTC vs. Prescription

Over-the-counter fish oil capsules typically contain 300-500 mg of combined EPA+DHA per capsule. Triglyceride-lowering effects require 2-4 g/day of EPA+DHA, which often means 4-8 capsules daily depending on concentration [14]. Prescription options deliver standardized doses in fewer capsules.

Icosapent ethyl (Vascepa) provides pure EPA at 2 g twice daily (4 g total). This is the formulation studied in REDUCE-IT and the one with the strongest cardiovascular outcome data [7]. Omega-3-acid ethyl esters (Lovaza) provide a mix of EPA and DHA at 4 g/day. The STRENGTH trial (N=13,078) tested a carboxylic acid formulation of EPA+DHA and did not show cardiovascular benefit, raising questions about whether DHA attenuates the benefits of EPA [15].

The 2019 NLA scientific statement noted: "The cardiovascular benefit demonstrated in REDUCE-IT appears specific to icosapent ethyl (pure EPA) at 4 g/day. Results should not be extrapolated to other omega-3 formulations" [16]. If your goal is cardiovascular risk reduction beyond triglyceride lowering, the evidence favors prescription EPA over mixed EPA/DHA supplements.

Monitoring When Taking Both

Standard lipid monitoring is sufficient. No additional tests are required specifically because of the combination.

Baseline and Follow-Up Labs

Check a fasting lipid panel before starting either agent. Repeat at 4-12 weeks after initiation to confirm response. For evolocumab, the primary metric is LDL-C reduction. For omega-3, watch triglyceride levels and (if using high-dose fish oil) check LDL-C, since DHA-containing formulations can raise LDL by 5-10% in some patients [14].

What to Watch For Clinically

Monitor for injection-site reactions with evolocumab (reported in 5.7% of patients in FOURIER vs. 4.7% on placebo) [6]. Omega-3 side effects at prescription doses include fishy aftertaste, GI discomfort, and loose stools. Neither agent causes the myalgias associated with statins.

If you are also on anticoagulation, request a CBC and coagulation studies at baseline and periodically thereafter. Report any unusual bruising, nosebleeds, or prolonged bleeding from cuts.

Who Benefits Most from the Combination?

Not every patient on Repatha needs omega-3, and not every fish oil user needs a PCSK9 inhibitor. The combination makes the most clinical sense in specific scenarios.

Mixed Dyslipidemia with Residual Risk

Patients who have achieved LDL-C goals on evolocumab (plus or minus a statin) but still carry triglycerides above 150 mg/dL have residual risk that omega-3 can address. The PROMINENT trial demonstrated that not all triglyceride-lowering agents reduce cardiovascular events, reinforcing that the agent choice (specifically prescription EPA) matters as much as the triglyceride number [17].

Familial Hypercholesterolemia with Hypertriglyceridemia

Patients with heterozygous familial hypercholesterolemia sometimes present with combined hyperlipidemia. The 2022 AHA scientific statement on FH recognized that triglyceride management is often overlooked in FH patients whose care focuses exclusively on LDL [18]. Adding prescription EPA to evolocumab therapy addresses both lipid abnormalities.

Post-ACS Patients on Aggressive Lipid Lowering

After an acute coronary syndrome event, guidelines recommend LDL-C below 55 mg/dL [13]. Many post-ACS patients are placed on high-intensity statins plus evolocumab. If triglycerides remain elevated, icosapent ethyl provides an additional 25% relative risk reduction for recurrent events based on REDUCE-IT subgroup data [7].

What to Tell Your Doctor

Bring a complete list of supplements to every cardiology visit. Fish oil is often treated as benign, but prescription-strength omega-3 is a pharmaceutical with measurable effects on bleeding time, LDL-C (in the case of DHA), and drug interactions with other agents you may be taking (anticoagulants, antiplatelet drugs).

Specifically, ask your prescriber three questions: (1) Is my triglyceride level high enough to benefit from prescription EPA? (2) Should I switch from OTC fish oil to icosapent ethyl for the cardiovascular outcome data? (3) Do any of my other medications interact with high-dose omega-3?

For patients already taking both Repatha and omega-3 without problems, no changes are necessary. Continue both and follow standard lipid monitoring at intervals your cardiologist recommends, typically every 3-6 months once stable.